ONYEKACHI EMMANUEL Vision University ANYAGWA

Dr. ONYEKACHI EMMANUEL Vision University ANYAGWA

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2024 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
ASAnastasiia D. Shkodina
Anastasiia D. Shkodina
MBMainak Bardhan
Mainak Bardhan
HCHITESH CHOPRA
HITESH CHOPRA
OAONYEKACHI EMMANUEL Vision University ANYAGWA
ONYEKACHI EMMANUEL Vision University ANYAGWA
VPViktoriia A. Pinchuk
Viktoriia A. Pinchuk
MDMykhailo Yu. Delva
Mykhailo Yu. Delva

12 June 2024 in Euroasian Journal of Hepato-Gastroenterology
Verified
Journal Article
Open access
VPVaibhavi S Patel
Vaibhavi S Patel
SMSafa F Mahmood
Safa F Mahmood
KBKunal H Bhatt
Kunal H Bhatt
RKRichisha M Khemkar
Richisha M Khemkar
DJDevanshi R Jariwala
Devanshi R Jariwala
MKMaha Kassem
Maha Kassem
This meta-analysis's objective was to assess the effectiveness of ursodeoxycholic acid (UDCA) in the management of nonalcoholic fatty liver disease (NAFLD). Electronic databases like PubMed, Embase, Scopus, and Cochrane Library were thoroughly looked for randomized controlled trials determining ursodeoxycholic acid's (UDCAs) effectiveness on the serum liver function tests in NAFLD patients. After screening, seven randomized controlled trials were incorporated overall. Utilizing a fixed effects model, quantitative data synthesis was performed in R version 4.3.1. The meta-analysis showed significant reductions in alanine transaminase (ALT) (p ≤ 0.0001), aspartate transaminase (p = 0.0009), and gamma-glutamyl transferase (GGT) (p ≤ 0.0001) after UDCA therapy. However, significant reductions in bilirubin (p = 0.6989) and alkaline phosphatase (ALP) (p = 0.1172) levels were not noted. Sensitivity analysis by removing the studies with some concerns of bias was successful in demonstrating a remarkable reduction in heterogeneity for aspartate transaminase and ALP, which was also observed while performing the subgroup analyses via dosage. Ursodeoxycholic acid was beneficial in patients diagnosed with NAFLD as it significantly reduced aspartate transaminase, ALT and GGT levels. However, more randomized controlled trials are required to be conducted in the future to increase the certainty of the evident findings. This meta-analysis strengthens the evidence about the reductions in AST, ALT, and GGT levels observed with ursodeoxycholic acid therapy in NAFLD patients by pooling the data together from the latest RCTs thus proving its hepatoprotective effects which can be beneficial in preventing the associated complications. Patel VS, Mahmood SF, Bhatt KH, et al. Ursodeoxycholic Acid's Effectiveness in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Euroasian J Hepato-Gastroenterol 2024;14(1):92–98.

8 June 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
FPFNU Parul
FNU Parul
TRTanya Ratnani
Tanya Ratnani
SSSachin Subramani
Sachin Subramani
HBHitesh Bhatia
Hitesh Bhatia
RARehab Emad Ashmawy
Rehab Emad Ashmawy
IPInderbir Padda
Inderbir Padda
Background: Chronic kidney disease (CKD) and its advanced stage, end-stage renal disease (ESRD), affect millions worldwide and are associated with a paradoxical hemostatic imbalance—marked by both increased thrombotic and bleeding risks—which complicates anticoagulant use and demands clearer, evidence-based clinical guidance. Design: This study is a critical review synthesizing the current literature on anticoagulant therapy in CKD and ESRD, with emphasis on altered pharmacokinetics, clinical complications, and therapeutic adjustments. Data Sources: PubMed, Scopus, and Google Scholar were searched for articles discussing anticoagulation in CKD/ESRD, focusing on pharmacokinetics, clinical outcomes, and dosing recommendations. Study Selection: Studies examining the safety, efficacy, and pharmacokinetics of anticoagulants—including heparin, low-molecular-weight heparin (LMWH), warfarin, and direct oral anticoagulants (DOACs)—in CKD and ESRD populations were included. Data Extraction and Synthesis: Key findings were summarized to highlight the dose modifications, therapeutic considerations, and clinical challenges in managing anticoagulation in CKD/patients with ESRD. Emphasis was placed on balancing thrombotic and bleeding risks and identifying gaps in existing guidelines. Results: Patients with CKD and ESRD exhibit a paradoxical hypercoagulable state marked by platelet dysfunction, altered coagulation factors, and vascular endothelial damage. This condition increases the risk of thrombotic events, such as deep vein thrombosis (DVT) and pulmonary embolism (PE), while simultaneously elevating bleeding risks. Hemodialysis and CKD-associated variables further complicate the management of coagulation. Among anticoagulants, unfractionated heparin (UFH) is preferred due to its short half-life and adjustability based on activated partial thromboplastin time (aPTT). Low-molecular-weight heparins (LMWHs) offer predictable pharmacokinetics but require dose adjustments in CKD stages 4 and 5 due to reduced clearance. Warfarin necessitates careful dosing based on the estimated glomerular filtration rate (eGFR) to maintain an international normalized ratio (INR) ≤ 4, minimizing bleeding risks. Direct oral anticoagulants (DOACs), particularly Apixaban, are recommended for patients with eGFR < 15 mL/min or those on dialysis, although data on other DOACs in CKD remain limited. The lack of comprehensive guidelines for anticoagulant use in CKD and ESRD highlights the need for individualized, patient-centered approaches that account for comorbidities, genetics, and clinical context. Conclusions: Managing anticoagulation in CKD/ESRD is challenging due to complex coagulation profiles and altered pharmacokinetics. Judicious dosing, close monitoring, and patient-centered care are critical. High-quality randomized controlled trials are needed to establish clear guidelines and optimize therapy for this vulnerable population.

8 July 2025 in Journal of Cancer Policy
Verified
Journal Article
Closed access
AAAjagbe Oluwasanmi Adekunle
Ajagbe Oluwasanmi Adekunle
AAAdegbesan Abiodun
Adegbesan Abiodun
AAAdewunmi Akingbola
Adewunmi Akingbola
Samuel TundealaoSamuel Tundealao
Samuel Tundealao
OAONYEKACHI EMMANUEL Vision University ANYAGWA
ONYEKACHI EMMANUEL Vision University ANYAGWA
JCJoel Chuku
Joel Chuku

18 February 2026 in Cardiovascular Diabetology – Endocrinology Reports
Verified
Journal Article
Open access
PDF file
PJPooja Joshi
Pooja Joshi
GRGriffin Rick
Griffin Rick
SMSrihitha Mesineni
Srihitha Mesineni
SBSujan Bohara
Sujan Bohara
SASehrish Atif
Sehrish Atif
OAONYEKACHI EMMANUEL Vision University ANYAGWA
ONYEKACHI EMMANUEL Vision University ANYAGWA
Treating hypertension in diabetic patients with antihypertensive medications should be done with careful consideration because these medications may interf

28 May 2026 in Global Surgical Education - Journal of the Association for Surgical Education
Verified
Journal Article
Closed access
BLBinh Le
Binh Le
LELily Ehsan
Lily Ehsan
OAONYEKACHI EMMANUEL Vision University ANYAGWA
ONYEKACHI EMMANUEL Vision University ANYAGWA
EEEmily Ehsan
Emily Ehsan
KBKeely Buesing
Keely Buesing
OSOlabisi Ololade Sheppard
Olabisi Ololade Sheppard